ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Saturday, September 12, 2015

Submitted by

Mark Ferguson

Source

Source Name: Lancet

Source URL: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60294-X/fullte…

Author(s)

Miklos Pless, Roger Stupp, Hans-Beat Ris, Rolf A Stahel, Walter Weder, Sandra Thierstein, Marie-Aline Gerard, Alexandros Xyrafas, Martin Früh, Richard Cathomas, Alfred Zippelius, Arnaud Roth, Milorad Bijelovic, Adrian Ochsenbein, Urs R Meier, Christoph Mamot, Daniel Rauch, Oliver Gautschi, Daniel C Betticher, René-Olivier Mirimanoff, Solange Peters on behalf of the SAKK Lung Cancer Project Group

This randomized trial compared induction therapy for pathologically-proven N2/IIIA NSCLC with 3 cycles of cisplatinum and docetaxel chemotherapy alone to chemotherapy combined with 44 Gy of radiation therapy. 232 pts in 23 centers were enrolled over a 12 year period. No differences were identified in the chemotherapy vs chemoradiotherapy groups for event-free survival (11.6 vs 12.8 mos) or median survival (26.2 vs 37.1).